Trials / Unknown
UnknownNCT02449343
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)
A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 233 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Compare the effects and safety of Anlotinib with placebo in patients with soft tissue sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib p.o. qd |
| DRUG | Placebo | Placebo p.o. qd |
Timeline
- Start date
- 2015-05-12
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2015-05-20
- Last updated
- 2017-04-25
Locations
25 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02449343. Inclusion in this directory is not an endorsement.